Skip to content
HowShorted

Stoke Therapeutics, Inc. short interest in 2021

In 2021, Stoke Therapeutics, Inc.'s disclosed short interest ran from 10.32% of shares outstanding on 15 Jan 2021 to 7.47% on 31 Dec 2021, a change of -2.85 percentage points. The year's high was 10.40% on 29 Jan 2021 and its low 3.79% on 30 Jul 2021, averaging 7.02% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.84 days on 26 Feb 2021. Full history: Stoke Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Stoke Therapeutics, Inc. in 2021

2021 in figures

Start of year
10.32% (15 Jan 2021)
End of year
7.47% (31 Dec 2021)
Change
-2.85 pp
High
10.40% (29 Jan 2021)
Low
3.79% (30 Jul 2021)
Average
7.02%
Highest days to cover
32.84 (26 Feb 2021)
SEC filings marked
9

Every report in 2021

Stoke Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202110.32%26.05results (8-K)
29 Jan 202110.40%30.11
12 Feb 202110.06%31.55
26 Feb 20219.85%32.84
15 Mar 20217.79%15.7510-K filed, results (8-K)
31 Mar 20218.62%13.70
15 Apr 20218.60%19.64
30 Apr 20218.16%13.18
14 May 20218.37%18.5910-Q filed, results (8-K)
28 May 20217.39%21.28
15 Jun 20216.63%18.14
30 Jun 20216.34%9.22
15 Jul 20215.59%15.65
30 Jul 20213.79%14.33
13 Aug 20213.96%10.3110-Q filed, results (8-K)
31 Aug 20214.22%19.72
15 Sep 20214.19%18.55
30 Sep 20215.38%10.71
15 Oct 20215.11%16.52
29 Oct 20215.50%21.51
15 Nov 20216.70%13.0010-Q filed, results (8-K)
30 Nov 20216.64%11.96
15 Dec 20217.34%9.77
31 Dec 20217.47%11.74

See also: Stoke Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.